复发性岛叶低级别胶质瘤:指导再次手术决策的因素
该回顾性连续队列研究纳入同一机构因岛叶低级别胶质瘤手术、肿瘤再生但无对比增强的80例患者,比较再次手术组(20例)与非再次手术组(60例)。首次手术切除程度(91.9% vs 89.7%,p=0.014)和残余肿瘤体积(9.5±7.1 mL vs 6.3±7.3 mL,p=0.02)与再次手术显著相关。作者认为经术中唤醒定位的再次手术与良好肿瘤学结局和低术后并发症相关。
要点
- 首次手术切除程度较高(91.9% vs 89.7%,p=0.014)与复发性岛叶低级别胶质瘤再次手术显著相关。
- 首次手术残余肿瘤体积较大(9.5±7.1 mL vs 6.3±7.3 mL,p=0.02)与再次手术显著相关。
- 肿瘤复发时左侧颞极浸润与前穿质浸润分别与再次手术正相关和负相关。
核心结论
- 在无影像学恶性转化证据的选择性复发性岛叶低级别胶质瘤患者中,经术中唤醒定位的再次手术与良好肿瘤学结局和低术后并发症相关。
研究设计与样本
- 回顾性连续队列研究,纳入同一机构因岛叶低级别胶质瘤手术、肿瘤再生但无对比增强的患者。
- 再次手术组20例,均为接受第二次切除的复发性岛叶低级别胶质瘤患者;非再次手术组60例,未接受再次手术而接受辅助肿瘤治疗。
主要发现
- 首次手术切除程度:再次手术组91.9% vs 非再次手术组89.7%,p=0.014。
- 首次手术残余肿瘤体积:再次手术组9.5±7.1 mL(范围0-30 mL) vs 非再次手术组6.3±7.3 mL(范围0-30 mL),p=0.02。
- 肿瘤复发时左侧颞极浸润:Liebermeister统计分析显示4293个体素通过错误发现率校正(p<0.05),最大z统计量=6.50。
- 肿瘤复发时前穿质浸润与再次手术显著负相关:179个体素通过错误发现率校正(p<0.05),最小z统计量=-4.33。
- 再次手术组平均切除程度83.7%,末次随访(9.3±3.8年)生存率90%,术后并发症低(95%患者卡氏功能状态评分≥80),术后恢复职业比例95%,癫痫控制率57.1%。
临床怎么用
- 作者认为,对于无影像学恶性转化证据的选择性复发性岛叶低级别胶质瘤患者,经术中唤醒定位的再次手术与良好肿瘤学结局和低术后并发症相关。
- 作者认为,首次手术切除程度较高和残余肿瘤体积较低与再次手术显著相关。
- 作者认为,受益于第二次手术的患者通常表现为皮质区域内复发模式(如颞极区域),而其他患者通常表现为前穿质及周围白质传导束内的深部浸润模式。
- 作者认为,这些原创发现可能有助于选择复发性岛叶低级别胶质瘤再次手术的最佳适应证。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Reoperation has been established as an effective therapeutic strategy in recurrent diffuse low-grade gliomas (LGGs). Insular gliomas represent a specific surgical challenge because of the surrounding vascular and functional structures. The aim of this study was to investigate the main clinicoradiological factors guiding the decision to reoperate on recurrent insular LGGs (ILGGs). METHODS: In this retrospective consecutive series, the authors screened all patients operated on for an ILGG in their institution who further presented with a tumor regrowth without the development of contrast enhancement. They compared patients who were subsequently offered a reoperation under awake mapping at recurrence or who underwent reoperation after adjuvant treatment had reduced the volume of the initial tumor recurrence (with a proven pathological diagnosis of LGG after the second surgery) to patients who were not selected for a reoperation. The first group (reoperated group; n = 20) included all recurrent ILGG patients who underwent second resection, and the second group (nonreoperated group; n = 60) included patients who did not undergo reoperation but underwent adjuvant oncological treatment. RESULTS: Factors significantly associated with reoperation were extent of resection (EOR) at first surgery (91.9% vs 89.7%, p = 0.014), residual tumor volume (9.5 ± 7.1 mL [range 0-30 mL] vs 6.3 ± 7.3 mL [range 0-30 mL], p = 0.02) at first surgery and left temporopolar infiltration at the time of tumor recurrence (Liebermeister statistical analysis, 4293 voxels survived false discovery rate correction with p < 0.05; maximal z-statistic = 6.50). Infiltration of the anterior perforated substance at tumor recurrence was significantly anticorrelated to reoperation (179 voxels survived false discovery rate correction with p < 0.05; minimal z-statistic = -4.33). The mean EOR was 83.7% at reoperation with a 90% survival rate at last follow-up (9.3 ± 3.8 years), low postsurgical morbidity (Karnofsky Performance Status score ≥ 80 in 95% of patients), a high rate of postoperative professional resumption (95%), and seizure control in 57.1% of patients. CONCLUSIONS: In selected patients with recurrent ILGG without radiographic evidence of malignant transformation, reoperation with intraoperative awake mapping is associated with favorable oncological outcomes and a low postsurgical morbidity. A greater EOR and a lower residual tumor volume at first surgery were significantly associated with reoperation. Patients who benefited from a second surgery typically had a recurrent pattern within cortical areas (such as the temporopolar region), while other patients typically presented with a deeper infiltrative pattern within the anterior perforated substance and the surrounding white matter pathways. Such original findings may be helpful to select the optimal indications of reoperation in recurrent ILGG.
引用
- Ribeiro L, Ng S, Duffau H, et al. Recurrent insular low-grade gliomas: factors guiding the decision to reoperate. J Neurosurg. 2022. PMID: 36308479. doi:10.3171/2022.9.JNS221286
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。